1132 completed, 356 terminated, 301 recruiting, 175 unknown. 1142 Phase 2, 792 Phase 1, 205 Phase 3, 146 Not applicable, 30 Phase 4.
Follow Myelodysplastic Syndromes: new trials by email Literature Review of Myelodysplastic Syndromes trials Research Report on Myelodysplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BLEX 404 Oral Liquid - Myelodysplastic Syndrome (MDS) | Phase 2 | Not yet recruiting | BioLite, Inc. | 52 | 2027-01-01 | 2026-04-13 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) Allogeneic umbilical cord mesenchymal stem cells, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. FXS6837 Capsule, Eculizumab infusion - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 90 | 2026-12-10 | 2026-08-05 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | University of Arizona | 180 | 2026-11-30 | 2026-10-22 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions Ofirnoflast - Myelodysplastic Syndromes, Anemia | Phase 2 | Not yet recruiting | Halia Therapeutics, Inc. | 70 | 2026-11-01 | 2026-10-02 |
| Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria SGB-9768 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 24 | 2026-10-31 | 2026-09-04 |
| A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy VSA012, Eculizumab (Soliris®) - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Not yet recruiting | Bisirna Therapeutics (Suzhou) Co., Ltd. | 70 | 2026-10-29 | 2026-09-11 |
Showing 20 of 2301. Sign in to see all of them.
Leukemia, Myeloid, Acute (1154) · Leukemia (597) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (568) · Leukemia, Myelomonocytic, Chronic (402) · Lymphoma, Non-Hodgkin (363) · Myeloproliferative Disorders (358) · Multiple Myeloma (334) · Leukemia, Lymphocytic, Chronic, B-Cell (325) · Lymphoma (318) · Anemia, Refractory, with Excess of Blasts (317) · Hodgkin Disease (316) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (280) · Primary Myelofibrosis (218) · Lymphoma, Mantle-Cell (195)
Hemic and Lymphatic Diseases (2301) · Bone Marrow Diseases (2278) · Hematologic Diseases (2248) · Neoplasms by Histologic Type (1565) · Neoplasms (1529) · Leukemia, Myeloid (1335) · Leukemia (942) · Pathological Conditions, Signs and Symptoms (890) · Pathologic Processes (872) · Immune System Diseases (848) · Disease Attributes (826) · Immunoproliferative Disorders (800) · Lymphatic Diseases (788) · Chronic Disease (773) · Lymphoproliferative Disorders (771)
Cyclophosphamide (254) · Azacitidine (235) · fludarabine phosphate (216) · fludarabine (178) · Busulfan (164) · Mycophenolic Acid (143) · Tacrolimus (140) · Whole-Body Irradiation (139) · Cytarabine (130) · Peripheral Blood Stem Cell Transplantation (116) · Decitabine (115) · Antilymphocyte Serum (114) · Cyclosporine (108) · Melphalan (105) · Filgrastim (103)
M.D. Anderson Cancer Center (149) · Fred Hutchinson Cancer Center (80) · National Cancer Institute (NCI) (71) · Novartis Pharmaceuticals (52) · Memorial Sloan Kettering Cancer Center (51) · Masonic Cancer Center, University of Minnesota (50) · Celgene (45) · City of Hope Medical Center (42) · National Heart, Lung, and Blood Institute (NHLBI) (38) · Alexion Pharmaceuticals, Inc. (32) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (32) · Washington University School of Medicine (30) · Groupe Francophone des Myelodysplasies (27) · Case Comprehensive Cancer Center (22) · Dana-Farber Cancer Institute (22)
United States (1517) · France (229) · Germany (187) · Italy (175) · China (172) · United Kingdom (161) · Canada (139) · Spain (139) · South Korea (95) · Australia (94) · Belgium (85) · Netherlands (76) · Japan (63) · Czechia (56) · Israel (55)
Guillermo Garcia-Manero, MD (18) · Jorge Cortes, MD (9) · Brenda Sandmaier (7) · Claudio G. Brunstein, MD, PhD (7)
PMID 23524640, PMID 42013378, PMID 23065508, PMID 27400247, PMID 32499241, PMID 16609072, PMID 18997171, PMID 21403127, PMID 22430088, PMID 29674506, PMID 39079163, PMID 39535306, PMID 40073835, PMID 40694294, PMID 17021321, PMID 19179301, PMID 19230772, PMID 19546476, PMID 21715313, PMID 22133778, PMID 22740453, PMID 23260600, PMID 23790798, PMID 24777753, PMID 24786393, PMID 25425683, PMID 27658437, PMID 28651604, PMID 28870615, PMID 31375393, PMID 31375516, PMID 31527168, PMID 32556286, PMID 33811823, PMID 34526067, PMID 34847232, PMID 35007144, PMID 35869170, PMID 35998303, PMID 36823396, PMID 37196637, PMID 37341189, PMID 37595058, PMID 38017103, PMID 38065202, PMID 38477987, PMID 38702786, PMID 38727860, PMID 39283025, PMID 40447351
P30CA015704 (35), P30CA033572 (30), P30CA006973 (21), 2016 (16), 2017 (14), 2023 (14), P30CA043703 (14), 2019 (12), P30CA016672 (12), P01CA018029 (10), 2015 (9), 2018 (9), 2009 (8), P01CA015396 (8), P30CA022453 (8)